Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Sponsor
University of California, San Francisco
Study ID
NCT00416819
Status
Completed

Conditions

  • Brain and Central Nervous System Tumors
  • Lymphoma

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • filgrastim — BIOLOGICAL
  • rituximab — BIOLOGICAL
  • cytarabine — DRUG
  • etoposide phosphate — DRUG
  • leucovorin calcium — DRUG
  • methotrexate — DRUG
  • temozolomide — DRUG

Study Details

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This clinical trial is studying the side effects and best ways to give combination chemotherapy together with rituximab in treating patients with newly diagnosed primary CNS lymphoma.

Key Dates

Start date
Sep 30, 2003
Status verified
Aug 2015
Primary completion
Dec 31, 2005
Completion
Feb 29, 2012

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: methotrexate, leucovorin calcium, rituximab, and temozolomide
    Determine the rate of toxicity, in terms of percentage of patients with grade 4 neurotoxicity, in patients with untreated primary CNS lymphoma treated with induction therapy comprising high-dose methotrexate, leucovorin calcium, rituximab, and temozolomide followed by consolidation therapy comprising cytarabine and etoposide phosphate.

Primary Outcome Measure

rate of toxicity in patients with untreated primary CNS lymphoma [ Time Frame: up to 8 months ]

Related Studies